Literature DB >> 12379461

Oncogenic H-ras induces cyclin B1 expression in a p53-independent manner.

Carla Santana1, Enrique Ortega, Alejandro García-Carrancá.   

Abstract

The role of p53 in controlling the G2 checkpoint, in part by repressing cyclin B1 transcription, has been well established. However, accumulating evidence indicate that p53-independent pathways may also play an important role. Ras proteins have been shown to regulate G1/S, but also G2/M transitions. Since cyclin B1/cdc2 complex is the key regulator controlling the G2/M checkpoint, we were interested in addressing if the H-ras oncogene could regulate cyclin B1 expression in a p53-independent manner. We observed an induction of cyclin B1 promoter activity in the presence of H-ras oncogene in SW480 cells, which contain null p53 alleles. In addition, HeLa cells known to express the HPV18 E6 oncogene that inactivates p53, exhibited increased levels of cyclin B1 mRNA and protein when transfected with the H-ras oncogene. Higher expression of cyclin B1 correlated with higher levels of cyclin B1/cdc2 complex and kinase activity that interestingly, showed no inhibition at G2/M after DNA damage. These data suggest that H-ras participates in pathways that regulate cyclin B1 expression and therefore controls the G2/M checkpoint in a p53-independent manner.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379461     DOI: 10.1016/s0027-5107(02)00172-0

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cells.

Authors:  Michaele J Armstrong; Michael T Stang; Ye Liu; Jinbo Gao; Baoguo Ren; Brian S Zuckerbraun; Raja S Mahidhara; Quanhua Xing; Eva Pizzoferrato; John H Yim
Journal:  Cancer Lett       Date:  2011-12-23       Impact factor: 8.679

2.  Krüppel-like factor 5 promotes mitosis by activating the cyclin B1/Cdc2 complex during oncogenic Ras-mediated transformation.

Authors:  Mandayam O Nandan; Sengthong Chanchevalap; W Brian Dalton; Vincent W Yang
Journal:  FEBS Lett       Date:  2005-08-29       Impact factor: 4.124

3.  A prognostic signature of G(2) checkpoint function in melanoma cell lines.

Authors:  Bernard Omolo; Craig Carson; Haitao Chu; Yingchun Zhou; Dennis A Simpson; Jill E Hesse; Richard S Paules; Kristine C Nyhan; Joseph G Ibrahim; William K Kaufmann
Journal:  Cell Cycle       Date:  2013-03-01       Impact factor: 4.534

4.  Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression.

Authors:  William K Kaufmann; Kathleen R Nevis; Pingping Qu; Joseph G Ibrahim; Tong Zhou; Yingchun Zhou; Dennis A Simpson; Jennifer Helms-Deaton; Marila Cordeiro-Stone; Dominic T Moore; Nancy E Thomas; Honglin Hao; Zhi Liu; Janiel M Shields; Glynis A Scott; Norman E Sharpless
Journal:  J Invest Dermatol       Date:  2007-06-28       Impact factor: 8.551

5.  Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors:  Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

Review 6.  Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Authors:  Md Emranul Karim; Kyi Kyi Tha; Iekhsan Othman; Mohammad Borhan Uddin; Ezharul Hoque Chowdhury
Journal:  Pharmaceutics       Date:  2018-05-26       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.